logo

For the Inventor, By the Inventor

Bridgewater, NJ, United States of America

Valeant Pharmaceuticals International

Calculating rank
USPTO Granted Patents = 22

% Expired Patents = 36.4



Trademarks = 30

Forward Citations = 91

Loading Chart...
Loading Chart...

26 inventors (with patents filed for the assignee):

goldMedal Jean-Michel Andre Vernier (12 out of 56 patents)

silverMedal Huanming Chen (11 out of 15 patents)

bronzeMedal Jim Zhen Wu (6 out of 11 patents)

4.  Jianlan Song (6 out of 6 patents)

5.  Martha Alicia De La Rosa (4 out of 24 patents)

6.  Valery Rubinchik (2 out of 12 patents)

7.  Charles Richard Kjellbotn (2 out of 5 patents)

8.  Greg Heacock (2 out of 2 patents)

9.  Louise Culham (2 out of 7 patents)

10.  Wes A Williams (2 out of 2 patents)

11.  Ni'Kita Wilson (2 out of 5 patents)

12.  Gary Lee Larson (2 out of 2 patents)

13.  Ian Wayne Cheney (2 out of 2 patents)

14.  Irwin Palefsky (2 out of 5 patents)

15.  Nikolaos Loupis (1 out of 47 patents)


22 patents:

1. 9949877 - Photodynamic therapy laser (2018-04-24),
2. 9655829 - Compositions and methods for teeth whitening (2017-05-23),
3. 9226917 - Photodynamic therapy for conditions of the eye (2016-01-05),
4. 9211214 - Photodynamic therapy laser (2015-12-15),
5. 8993593 - N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators (2015-03-31),
6. 8859618 - Silicone gel-based compositions for wound healing and scar reduction (2014-10-14),
7. 8852629 - Drug delivery system for hydrophobic drugs (2014-10-07),
8. 8722929 - N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators (2014-05-13),
9. 8563604 - Silicone gel-based compositions for wound healing and scar reduction (2013-10-22),
10. 8563566 - Naphthyridine derivatives as potassium channel modulators (2013-10-22),
11. 8492588 - Benzyloxy anilide derivatives useful as potassium channel modulators (2013-07-23),
12. 8367684 - Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators (2013-02-05),
13. 8338487 - [object Object] (2012-12-25),
14. 8293911 - Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators (2012-10-23),
15. 8211918 - Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators (2012-07-03),
Company Overview
Valeant Pharmaceuticals International, now known as Bausch Health Companies Inc., is a global healthcare company focused on developing, manufacturing, and marketing a diverse range of pharmaceutical products. The organization specializes in dermatology, ophthalmology, and gastrointestinal health, among other therapeutic areas. With a commitment to innovation, Valeant leverages advanced research and technology to enhance patient care and improve health outcomes across various markets, primarily in North America and beyond.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

Valeant Pharmaceuticals International USPTO Patent Assignee Logo
22 Patents

#16 in Bridgewater, NJ

#579 in New Jersey

#15,057 in US

#28,822 in the World

Bridgewater, NJ (US)
Bridgewater, NJ, United States of America

Valeant Pharmaceuticals International

Forward Citations = 91

26 inventors:

goldMedal Jean-Michel Andre Vernier (12 out of 56 patents)

silverMedal Huanming Chen (11 out of 15 patents)

bronzeMedal Jim Zhen Wu (6 out of 11 patents)

4.  Jianlan Song (6 out of 6 patents)

5.  Martha Alicia De La Rosa (4 out of 24 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Valeant Pharmaceuticals International. Retrieved from https://idiyas.com/company/valeant-pharmaceuticals-international

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…